Hyderabad23 minutes ago
- copy link
So far, Covaxin has been approved for emergency use in 13 countries. At the same time, the process for this is going on in 60 countries.
Bharat Biotech has joined hands with American company Occugen Inc for the co-development, manufacturing and commercial use of its corona vaccine Covaxin in Canada. The company gave this information on Thursday. Occugen Inc. is also a partner of Bharat Biotech in the US. Now Canada has also been included in their agreement.
Bharat Biotech had earlier informed on February 2 that it has tied up with Occugen Inc. for co-development, supply and commercial use of Covaxin in the US. Shankar Musunuri, co-founder and CEO of Occugen, said that the company is working towards applying for the emergency use of the vaccine in the US. Now we will also seek approval from the regulatory body in Canada under an interim order.
Occugen will keep 45% of the profits
Shankar said that the inclusion of the Canadian market in the agreement reflects our strong relationship. With this, we will be able to take a unique, but traditional vaccine to more countries. In a release issued by the company, it has been said that both the companies will share profits in Canada like America. Occugen will keep 45% of the profits from the sale of Covaxin in Canada.
Covaxin is effective on every variant
Krishna Ella, Chairman and Managing Director, Bharat Biotech, said that Covaxin has demonstrated an excellent safety record in clinical trials and emergency use in India. Its 30 million doses have been supplied in India and other countries. There were no safety issues anywhere in this. So far, Covaxin has been approved for emergency use in 13 countries. At the same time, its process is going on in 60 countries.
He said that we are working with Occugen to bring Covaxin to the US. Now want to bring it to the Canadian market. Bharat Biotech believes that Covaxin is essential for everyone, including children, as it is effective against all variants of the virus.